A Phase 1,Randomized, Single-blind, Placebo-controlled, Single Dose, Dose-escalated Study to Assess the Safety, Pharmacokinetic and Pharmacodynamic Profile of Subcutaneous Administration of a Long-acting Recombinant Factor VIIa in Healthy Adult Males

Trial Profile

A Phase 1,Randomized, Single-blind, Placebo-controlled, Single Dose, Dose-escalated Study to Assess the Safety, Pharmacokinetic and Pharmacodynamic Profile of Subcutaneous Administration of a Long-acting Recombinant Factor VIIa in Healthy Adult Males

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Factor VIIa-CTP (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Adverse reactions
  • Sponsors OPKO Health
  • Most Recent Events

    • 09 Nov 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
    • 09 Nov 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Mar 2018.
    • 09 May 2017 Status changed from not yet recruiting to recruiting, as reported in a OPKO Health media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top